(Q37349771)

19 August 2017

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort (English)

1 reference

19 August 2017

1 reference

Stefan Braune

1

1 reference

19 August 2017

M Lang

series ordinal

2

1 reference

19 August 2017

A Bergmann

series ordinal

3

1 reference

19 August 2017

NTC Study Group

series ordinal

4

1 reference

19 August 2017

6 September 2013

1 reference

19 August 2017

1 reference

19 August 2017

260

1 reference

19 August 2017

12

1 reference

19 August 2017

2981-2985

1 reference

Creative Commons Attribution 2.0 Generic

19 August 2017

start time

6 September 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s00415-013-7082-0

0 references

cites work

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3843369

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3843369

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3843369

Stratification for the propensity score compared with linear regression techniques to assess the effect of treatment or exposure.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3843369

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3843369

The central role of the propensity score in observational studies for causal effects

2 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-013-7082-0

10.1007/S00415-013-7082-0

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference

19 August 2017

1 reference